The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.

The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.

The present application is directed to transdermal formulations comprising one or more capsaicinoinds, one or more 1,4-dialdehyde sesquiterpenes, a penetration enhancer comprising tetrahydropiperine and a transdermal formulation base. The formulations advantageously show improved color characteristics and cause less irritation compared to other known transdermal or topica formulations comprising capsaicinoinds.

Methods of extracting anthocyanins from corn kernels are disclosed. In embodiments, the methods may include fractionating the corn kernels into their constituent component parts. After fractionating, the pericarp fiber may be separated from the constituent component parts of the corn kernels. The pericarp fiber may be steeped in an aqueous solution to extract anthocyanins from the pericarp fiber. After steeping, the aqueous solution may contain greater than about 40% by weight of total extractable anthocyanins present in the corn kernels prior to fractionating.

Methods of extracting anthocyanins from corn kernels are disclosed. In embodiments, the methods may include fractionating the corn kernels into their constituent component parts. After fractionating, the pericarp fiber may be separated from the constituent component parts of the corn kernels. The pericarp fiber may be steeped in an aqueous solution to extract anthocyanins from the pericarp fiber. After steeping, the aqueous solution may contain greater than about 40% by weight of total extractable anthocyanins present in the corn kernels prior to fractionating.

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds inhibit PD-1/PD-L1 interaction and are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

##STR00001##

The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.